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Abstract
To investigate how changes in eGFR can affect medical costs, a regional cohort of national
health insurance beneficiaries in Japan was developed from a nationwide database system
(Kokuho database, KDB), and non-individualized data were obtained. From 105,661 people,
subjects on chronic dialysis and subjects without consecutive medical checkups were
excluded. Finally, medical costs in the follow-up year categorized by annual changes in
eGFR between baseline and the next year were longitudinally examined in 70,627 people
ranging in age from 40 to 74 years. Global mean costs for subjects with a rapid decrease in
eGFR (�-30%/year) were the highest among all ΔeGFR categories. In men, the cost was
1.42 times that for a stable eGFR. A total of 6,268 (19.4%) men and 5,381 (14.0%) women
with eGFR <60 ml/min/1.73 m2 were identified in the baseline year. The mean cost was
higher with a low eGFR than without a low eGFR, and there were also higher proportions
newly initiating dialysis in 2014 (low eGFR with rapid decrease in eGFR vs. with stable
eGFR: 9.61% vs. 0.02% in women, P<0.001). Moreover, the costs for low eGFR subjects
with a rapid decrease in eGFR were more than twice those of non-low eGFR subjects with a
rapid decrease in eGFR and also compared to low eGFR subjects with a stable eGFR.
Moreover, initiating chronic dialysis was considered one of the major causes of high medical
costs in women with rapid eGFR decline. To the best of our knowledge, this is the first study
of renal disease using a cohort developed from the KDB system recently established in
Japan.
Introduction
Chronic kidney disease (CKD) is a risk factor for not only progression to end-stage kidney
disease (ESKD), but also for the development of cardiovascular disease (CVD) and all-cause
mortality [1–7]. Therefore, CKD patients often develop ESKD and CVD, which generally
require expensive treatment modalities and hospitalization. Recent cross-sectional studies
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demonstrated medical cost increases as estimated glomerular filtration rate (eGFR) decreases
[8,9]. However, these investigations did not take variations of renal function and proteinuria
into consideration. Recently, an annual decline of GFR has attracted attention as a risk factor
for mortality, the incidence of ESKD, and the incidence of CVD [10–14], and change in the
eGFR is becoming a promising surrogate marker for clinical endpoints [10–17]. Thus, we
hypothesized that the costs for CKD patients with a rapid decline in eGFR are much greater
than for those with stable renal function and without proteinuria, because of initiating and tak-
ing chronic dialysis, intensive medication, or other multidisciplinary treatment of complica-
tions along with CKD progression.
To address this issue, using a national health insurance cohort of (Kokumin-Kenkou
Hoken in Japanese; in short, Kokuho) beneficiaries in Japan, aged from 40 to 74 years, total
medical costs in the follow-up year categorized by annual changes in eGFR between baseline
and the next year were longitudinally examined. Furthermore, whether the annual change in
eGFR can discriminate medical costs in the subpopulation with CKD determined by reduced
GFR and proteinuria at baseline was examined. To the best of our knowledge, the precise rela-
tionship between changes in eGFR and medical costs has not been examined. In addition, this
is the first attempt to use a large-sized cohort of more than 100,000 people from the recently
established Kokuho database (KDB) for research on renal diseases in Japan. These analyses
might demonstrate the impact of a rapid decline in renal function in CKD patients on medical
costs for treating CKD, initiating chronic dialysis, and other diseases associated with CKD.
Methods
Study population
Everyone living in Japan is required to enroll in one of the many insurance systems. Kokuho,
which is for self-employed individuals, as well as for retirees and their dependents, covered
40.1% of the total Japanese population in 2012 [18]. The study cohort consisted of Japanese
Kokuho beneficiaries, aged 40–74 years, living in Japan. The study population included
105,661 people who had undergone annual specific health checkups in 2012 according to “The
Specific Health Check and Guidance in Japan” [19]. Thus, most of the study participants were
relatively healthy, community-dwelling residents. Annual claim files from Kokuho in 2014
after the primary survey were linked to the baseline data in the KDB system. The names,
address, and any other personalized data of the participants were completely deleted from the
linked data to protect their privacy. Moreover, the researchers could only report aggregate
data, not individualized data.
Participants on chronic dialysis (N = 74) until the end of 2013 and not having consecutive
medical checkups in 2013 (N = 34,283) and subjects with missing data (N = 677) were
excluded. Finally, the subjects included 70,627 people [54.2% were women] from 40 to 74
years of age, for whom all of the data necessary for this study were available, namely, informa-
tion about age, sex, height, weight, systolic blood pressure, diastolic blood pressure, habitual
smoking, use of antihypertensive drugs, lipid-lowering drugs, and hypoglycemic drugs,
obtained via a self-reported questionnaire, in addition to data concerning the serum creatinine
level and dipstick urine test for proteinuria (Fig 1). The institutional review board for ethical
issues of the University of Tsukuba approved this study (No. 999, UMIN: 000019774)
Baseline examination
Serum creatinine was measured using the enzymatic method, and eGFR (ml/min/1.73 m2) was
calculated using the formula of the Japanese Society of Nephrology [20]. Annual change in
eGFR was determined using data in 2012 and 2013, defined as [(eGFR in 2013 –eGFR in 2012)
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/ eGFR in 2012 x (interval months/12)]. As other methodologies were described in detail previ-
ously [10], urinalysis by the dipstick method was performed on a single spot urine specimen.
Urine dipstick results were interpreted by the medical staff at each local medical institution and
recorded as (−), (+/−), (+), (2+), and (3+) as described previously [21]. In Japan, the Japanese
Committee for Clinical Laboratory Standards (http://jccls.org/) proposes that all urine dipstick
results of (+) should correspond to a urinary protein level of 30 mg/dl. Proteinuria was defined
as (+) or more. Blood samples were collected and assayed within 24 hours with an automatic
clinical chemical analyzer.
Follow-up and outcome analyses
The incidence of starting chronic dialysis in this study was defined as no record during the pri-
mary survey years (namely, in 2012 and 2013) and an existing record for chronic dialysis ther-
apy in the follow-up year (namely, in 2014). In Japan, since one can discriminate claims for
medical costs for hospitalized patients and outpatients, “inpatient” was defined as an individ-
ual having a claim as a hospitalized patient of more than one yen, while “outpatient” was
defined as having any claim as an outpatient, but no claims as a hospitalized patient. “No
claim” was defined as having claims neither as an inpatient nor or as an outpatient during fol-
low-up. Medical costs for the study participants were calculated by summing their claims for
the 12 months of 2014.
Statistical analysis
The outcomes for the analysis were the incidence of starting dialysis during the follow-up
period and the mean medical cost among the subpopulations divided by changes in eGFR dur-
ing the primary survey years. Categorical variables are presented as percentages and continu-
ous variables as means and standard deviation (Table 1). Differences in every variable and
mean medical cost were first compared among four categories by change in eGFR (�-30%, -30
to -15%, -15 to +15%, and>+15% per year) using the chi-squared test or one-way analysis of
Fig 1. Study design. Strategy for recruitment of the study population, follow-up, and outcome analyses. Abbreviations: KDB, Kokuho database;
eGFR, estimated glomerular filtration rate; ΔGFR, annual change in eGFR.
https://doi.org/10.1371/journal.pone.0216432.g001
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variance (ANOVA), as appropriate. Student’s t-test or Mann-Whitney’s test was used as
appropriate to comparing mean or median medical costs between stable eGFR (-15 to +15%
per year) and other categories of eGFR change. A p value of<0.05 was considered significant.
Statistical analyses and graphical analyses were performed using SPSS version 24, Stata version
14 and GraphPad Prism version 6.
Results
During the follow-up period (i.e. 2014), 22 (15 men and 7 women) of the 70,627 study subjects
started chronic dialysis (Figs 1 and 2 and S1 Table). Their mean medical costs in 2014 are
Table 1. Demographics of the study population.
Men
Annual change in eGFR (%/year) �-30 -30 - -15 -15 - +15 >+15
Study size (persons) 776 3725 25321 2476
Age (years) 62 ± 9 63 ± 9 62 ± 9 62 ± 9 0.056
Systolic blood pressure (mmHg) 132 ± 17 130 ± 16 128 ± 16 128 ± 16 < 0.001
Diastolic blood pressure (mmHg) 77 ± 11 77 ± 10 77 ± 10 77 ± 11 0.613
Use of anti-hypertensive drugs (%) 45.4 42.3 38.8 42.4 0.007
Hemoglobin A1c (%) 5.9 ± 1.2 5.8 ± 0.9 5.7 ± 0.7 5.8 ± 0.7 < 0.001
Use of hypoglycemic drugs (%) 13.7 10.4 8.8 9.9 0.032
Triglycerides (mg/dl) 146 ± 111 142 ± 114 136 ± 104 143 ± 110 < 0.001
Low-density lipoprotein (mg/dl) 119.1 ± 32.9 118.5 ± 30.1 119.6 ± 29.3 120.1 ± 31.6 0.146
High-density lipoprotein (mg/dl) 55.7 ± 15.4 55.4 ± 14.5 55.7 ± 14.2 56.3 ± 14.8 0.098
Use of lipid-lowering drugs (%) 17.1 15.9 14.8 15.8 0.193
Smoking (%) 26.5 23.0 19.8 24.3 < 0.001
Body mass index (kg/m2) 25.1 ± 3.6 24.8 ± 3.4 24.8 ± 3.3 24.9 ± 3.5 0.003
Proteinuria at baseline (+ or more, %) 10.9 8.6 7.4 10.3 0.005
Baseline estimated GFR (ml/min/1.73 m2) 96.6 ± 37.7 85.4 ± 20.7 72.8 ± 15.3 67.5 ± 15.1 < 0.001
Estimated GFR in the next year (ml/min/1.73 m2) 67.2 ± 22.5 69.0 ± 16.5 71.4 ± 14.9 82.1 ± 19.0 < 0.001
Women
Annual change in eGFR (%/year) �-30 -30 - -15 -15 - +15 >+15
Study size (persons) 1412 5388 28217 3312
Age (years) 62 ± 9 63 ± 8 63 ± 8 63 ± 8 0.112
Systolic blood pressure (mmHg) 128 ± 18 127 ± 17 125 ± 17 125 ± 17 < 0.001
Diastolic blood pressure (mmHg) 74 ± 10 74 ± 10 74 ± 10 74 ± 11 0.073
Use of anti-hypertensive drugs (%) 35.1 36.1 32.2 34.2 0.007
Hemoglobin A1c (%) 5.8 ± 0.9 5.7 ± 0.7 5.7 ± 0.6 5.7 ± 0.7 < 0.001
Use of hypoglycemic drugs (%) 7.4 6.9 5.4 5.8 < 0.001
Triglycerides (mg/dl) 120 ± 78 113 ± 70 109 ± 64 113 ± 65 < 0.001
Low-density lipoprotein (mg/dl) 127.0 ± 31.8 125.3 ± 29.7 127.0 ± 29.9 128.4 ± 32.0 < 0.001
High-density lipoprotein (mg/dl) 60.7 ± 14.0 61.9 ± 14.5 63.3 ± 14.6 63.5 ± 15.1 < 0.001
Use of lipid-lowering drugs (%) 22.8 23.5 22.1 22.0 0.067
Smoking (%) 6.8 5.2 4.3 6.0 0.006
Body mass index (kg/m2) 24.3 ± 4.1 24.1 ± 4.0 23.8 ± 3.8 24.1 ± 4.0 < 0.001
Proteinuria at baseline (+ or more, %) 4.8 4.2 3.7 5.6 0.071
Baseline estimated GFR (ml/min/1.73 m2) 104.6 ± 32.4 88.7 ± 21.0 73.3 ± 15.2 68.3 ± 14.5 < 0.001
Estimated GFR in the next year (ml/min/1.73 m2) 69.5 ± 17.1 71.0 ± 15.4 72.2 ± 14.9 84.1 ± 19.7 < 0.001
Abbreviations: GFR, glomerular filtration rate; eGFR, estimated glomerular filtration rate
https://doi.org/10.1371/journal.pone.0216432.t001
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shown in Fig 2, and the costs of subjects starting dialysis in 2014 were more than 12 times
those who did not start dialysis (3,296,095 yen vs. 261,626 yen).
Comparisons of baseline characteristics among the subpopulations with a rapid decrease
(� -30% per year), decrease (-30 to -15% per year), stable (-15 to +15% per year), and increase
(<+15% per year) in eGFR are shown for men and women separately in Table 1. The popula-
tion with a stable eGFR was the largest (78.4% of men and 73.6% of women), and their eGFR
decreased from baseline (i.e. 2012) by 1.4 ml/min/1.73 m2 in men and 1.1 ml/min/1.73 m2 in
women in the next year (i.e. 2013). A rapid decrease in eGFR was seen in 2.4% of men and
3.6% of women, and they showed higher systolic blood pressure, hemoglobin A1c, rate of
using antihypertensive drugs and hypoglycemic drugs, triglycerides, rate of habitual smoking,
and body mass index, and they tended to have a higher rate of proteinuria.
Table 2 and S2 Table show the number of subjects without any claims (# No claim), with
claims not including hospitalization (# Outpatient), and with claims including hospitalization
(# Inpatient) in 2014 and their proportion in each ΔeGFR category and the mean medical cost
per person. The global mean costs for the subjects with a rapid decrease in eGFR were the
highest among all ΔeGFR categories, both in men and in women. In men, the cost was 1.42
times that for stable eGFR (385,956 yen vs. 270,897 yen). Particularly in men, but not in
women, the proportion of inpatients tended to be higher (15.2%) compared to other ΔeGFR
subpopulations (9 to 11%, P = 0.062).
When subdividing the subjects by renal function (60 ml/min/1.73 m2) for eGFR (G stage 3a
or worse) or the result of dipstick proteinuria (1+ or more) in the baseline year (namely, in
2012) according to the criteria of the CKD definition, 6,268 (19.4%) men and 5,381 (14.0%)
women with eGFR< 60 ml/min/1.73 m2 and 2,530 (7.8%) men and 1,529 (4.0%) women with
Fig 2. Mean medical costs in the 12 months among the subpopulations starting and not starting chronic dialysis.
Patients on chronic dialysis in the baseline year and/or the next year were excluded from the analysis. Therefore,
initiation of dialysis occurred in 2014. Error bars show the standard deviations. Abbreviations: eGFR, estimated
glomerular filtration rate; ΔGFR, annual changes in eGFR.
https://doi.org/10.1371/journal.pone.0216432.g002
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positive proteinuria were identified (Table 3 and S3 Table). Generally, the mean cost for the
subjects with a low eGFR or with positive proteinuria was higher than for subjects without a
low eGFR. There were also higher proportions of starting dialysis in 2014 (eGFR�60 vs.<60;
0.015% vs. 0.031% in men [P<0.001] and 0.000% vs. 0.018% [P<0.001] in women, Table 3).
In men and in women, mean medical costs for subjects with a rapid decrease in eGFR were
obviously the highest among all ΔeGFR categories in cases both with and without renal dys-
function. Moreover, the costs of low eGFR subjects with a rapid decrease in eGFR were more
than twice those of non-low eGFR subjects with a rapid decrease in eGFR and also compared
to low eGFR subjects with a stable eGFR. Subdividing the subjects with proteinuria in the base-
line year also significantly highlighted the massive cost for positive proteinuria subjects with a
rapid decrease in eGFR, suggesting that the effect of subdividing by proteinuria is consistent
with that of subdividing by eGFR of 60 ml/min/1.73 m2 (Table 3).
To demonstrate the impact of hospitalization on medical costs of each ΔeGFR subpopula-
tion, inpatient costs and outpatient costs were further analyzed separately and compared using
the mean cost for subjects with a stable eGFR as the reference (Fig 3 and S4 Table). In subjects
with eGFR�60 ml/min/1.73 m2, the mean costs for inpatients and for outpatients were signifi-
cantly, but slightly, higher in men with a rapid decrease in eGFR than in the reference group
(Fig 3A). In men with eGFR<60 ml/min, the mean cost for inpatients was more than double
that compared to the reference group (127,548 yen vs. 304,259 yen), as well as for outpatients
(208,855 yen vs. 437,254 yen, Fig 3B). In women with eGFR <60 ml/min, specifically outpa-
tients, the mean cost was 2.5 times higher than the reference (204,816 yen vs. 521,292 yen, Fig
3D).
Table 2. Mean medical cost, numbers of subjects with or without claims and starting chronic dialysis in the subpopulations based on annual changes in eGFR.
ΔeGFR category �-30 -30 - -15 -15 - +15 >+15 ANOVA, P Chi-squared, P
Men, mean cost, yen 385,956 277,329 270,897 323,333 < 0.001 0.009
# No claim 118 508 3600 313
% 15.2 13.6 14.2 12.6 0.979
Mean cost, yen 0 0 0 0 > 0.999
# Outpatient 540 2854 19115 1879
% 69.6 76.6 75.5 75.9 0.029
Mean cost, yen 206,201 189,114 173,416 193,545 < 0.001
# Inpatient 118 363 2606 284
% 15.2 9.7 10.3 11.5 0.062
Mean cost, yen 1,594,520 1,359,009 1,360,143 1,538,383 0.141
# Initiation Dialysis 4 2 7 2
Women, mean cost, yen 271,159 253,812 244,757 270,362 0.027 0.985
# No claim 153 597 2969 370
% 10.8 11.1 10.5 11.2 0.999
Mean cost, yen 0 0 0 0 >0.999
# Outpatient 1145 4384 22931 2660
% 81.1 81.4 81.3 80.3 >0.999
Mean cost, yen 200,871 187,261 174,125 190,196 < 0.001
# Inpatient 114 407 2317 282
% 8.1 7.6 8.2 8.5 0.999
Mean cost, yen 1,341,053 1,342,967 1,257,424 1,381,264 0.414
# Initiation Dialysis 5 1 1 0
Abbreviations: eGFR, estimated glomerular filtration rate; ΔGFR, annual changes in eGFR.
https://doi.org/10.1371/journal.pone.0216432.t002
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Discussion
This study examined how the changes in renal function affect medical costs in the following
year using the database of the KDB system to identify subsequent results of health checkups
and medical claims. As far as we know, there have been no previous attempts to use cohort
data from the recently established KDB system for research on renal diseases. The present
strategy that linked three years (2012 to 2014) succeeded in identifying the subpopulation that
started chronic dialysis with eGFR data in the prior two years (Fig 1). Throughout Japan, the
number of patients starting chronic dialysis was 39,344 in 2016 [22], and the crude rate com-
pared to the general population (127 million) was estimated to be 0.031%. This rate is almost
the same as found in this study population, 22 of 70,627 (0.031%), though the age of the sub-
jects ranged from 40 to 75 years, which is the age for annual specific health checkups.
CKD is a risk factor for progression to ESKD, development of CVD, and all-cause mortality
[1–7]. Therefore, patients with CKD often develop ESKD requiring chronic dialysis and life-
Table 3. Mean medical costs, numbers of subjects, and starting chronic dialysis in the subpopulations based on eGFR or proteinuria at baseline and on annual
changes in eGFR.
ΔeGFR category �-30 -30 - -15 -15 - +15 >+15 ANOVA, P
Low eGFR (<60 ml/min/1.73 m2) Men, % 9.41 8.99 19.91 33.04 < 0.001
No Mean cost, yen 349,035 263,326 254,611 295,365 < 0.001
# 703 3390 20279 1658
Incident dialysis, (#) 1 0 3 1
Yes Mean cost, yen 741,513 419,036 336,402 380,021 < 0.001
# 73 335 5042 818
Incident dialysis, (#) 3 2 4 1
Women, % 3.68 4.25 15.12 25.18 < 0.001
No Mean cost, yen 257,686 243,969 234,476 264,007 < 0.001
# 1360 5159 23951 2478
Incident dialysis, (#) 0 0 0 0
Yes Mean cost, yen 623,547 475,570 302,478 289,243 < 0.001
# 52 229 4266 834
Incident dialysis, (#) 5 1 1 0
Proteinuria at baseline Men, % 10.89 8.60 7.43 10.25 0.011
Negative Mean cost, yen 356,600 262,744 262,257 304,439 < 0.001
# 687 3390 23348 2215
Incident dialysis, (#) 1 1 6 1
Positive Mean cost, yen 641,752 425,617 366,523 477,199 < 0.001
# 84 319 1874 253
Incident dialysis, (#) 3 1 1 1
Missing consecutive urinalysis # 5 16 99 8
Women, % 4.75 4.25 3.74 5.55 0.127
Negative Mean cost, yen 257,793 246,704 240,559 264,323 < 0.001
# 1,343 5138 27049 3114
Incident dialysis, (#) 0 0 0 0
Positive Mean cost, yen 546,868 416,280 337,436 380,172 < 0.001
# 67 228 1051 183
Incident dialysis, (#) 5 1 1 0
Missing consecutive urinalysis # 2 22 117 15
Abbreviations: eGFR, estimated glomerular filtration rate; ΔGFR, annual changes in eGFR.
https://doi.org/10.1371/journal.pone.0216432.t003
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threating complications such as CVD requiring intensive care and hospitalization. As a result,
it was demonstrated that medical costs increase as eGFR decreases [8,9]. However, that evi-
dence was based on only one test during screening of serum creatinine and proteinuria.
Recently, change in eGFR has been considered to predict the incidence of ESKD and its com-
plications including CVD, and it could be used as a promising surrogate marker for clinical
outcomes [15–17], but there has been little evidence on whether changes in eGFR are involved
in actual medical costs as consequences of ESKD and other causes.
Definitions and the cutoff point of ΔeGFR have not been settled in clinical studies. How-
ever, ΔeGFR was defined as [(eGFR at baseline–eGFR at last follow-up) / eGFR at baseline]
in most studies, and a 30% decline in eGFR during follow-up that ranged from one to three
years was used for the cut-off based on predicting ESKD [23,24]. They recommended using
repeated creatinine measurements with a 2- or 3- year interval rather than a one-year interval,
because a longer-term observation period results in more accurate evaluation of ΔeGFR and
better prediction of the incidence of ESKD [17,23,24]. The present data used an interval of
Fig 3. Mean inpatient costs and outpatient costs in the subpopulations based on eGFR at baseline and on annual changes in eGFR. Mean
inpatient cost (black bars) and mean outpatient cost (white bars) with standard error of the mean (error bars) shown by category of ΔGFR. The costs
for subjects with preserved renal function at baseline (eGFR�60 ml/min/1.73 m2) have significant but small differences between a rapid decrease in
eGFR (-30 to -15% per year) and stable eGFR (-15 to +15% per year) as the reference in men (A) and women (B). Subjects with reduced renal
function at baseline (eGFR<60 ml/min/1.73 m2) have dramatically higher costs when their eGFR rapidly decreases compared to the stable
(reference) group in men (C) and women (D). �P<0.05, ��P<0.01, ���P<0.001 when comparing to the reference (-15 to +15% per year).
Abbreviations: eGFR, estimated glomerular filtration rate; ΔGFR, annual changes in eGFR; ref., Reference.
https://doi.org/10.1371/journal.pone.0216432.g003
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“approximately” one-year, that is no more than two years. Therefore, to pursue analytical accu-
racy, we consider it is better to correct by the interval of measurement, because it was
12.6 ± 2.4 (mean ± standard deviation) months in men and 12.6 ± 2.5 months in women.
Subjects with a rapid decrease in eGFR generally have worse co-morbid conditions (hyper-
tension, hyperglycemia, and dyslipidemia) and worse physical status (higher BMI) compared
to other ΔeGFR categories (Table 1). As a consequence, it was thought that they would incur
the highest gross mean cost in the following year (Table 2). The major component of the
higher burden in men seems to be the low outpatient proportion and the high inpatient pro-
portion, suggesting a higher frequency of diseases requiring hospitalization in men with a
rapid decrease in eGFR. Complications in progressive CKD patients, generally speaking CVD,
though there was no evidence in this study, are considered to be the major determinants of
medical costs in the men of this study population. On the other hand, in women, a rapid
decrease in eGFR had little effect on mean medical costs compared to a stable eGFR (271,159
yen vs. 244,757 yen, Table 2), partially because of no difference in the frequency of inpatient
and outpatient visits among ΔeGFR categories, unlike in men.
Decreases in eGFR in CKD and non-CKD patients should be assessed for the risk of inci-
dent and all-cause mortality, because the eGFR slope in CKD with eGFR <60 ml/min/1.73 m2
is more significant and sensitive than eGFR�60 ml/min/1.73 m2 [25]. Consistent with this,
subdividing the study population by eGFR or proteinuria can highlight the importance of
ΔeGFR in women for medical costs and starting chronic dialysis (Table 3). Women with CKD
and a rapid decrease in eGFR have a much higher frequency of starting chronic dialysis com-
pared to those with a stable eGFR with CKD (9.61% vs. 0.02% in women [P<0.001, Chi-
squared test], Table 3). Therefore, starting and being on chronic dialysis appear to be the
major causes of the higher mean cost in women with CKD and a rapid decrease in eGFR.
To the best of our knowledge, this is the first study to examine medical costs in a large-sized
(over a 100,000 subjects) general population with consecutive results for proteinuria and renal
function, consecutive medical claims, and dependency on chronic dialysis. Therefore, the pres-
ent strategy had the strength to perform sub-analyses of men and women enrolled and to iden-
tify the frequency of hospitalizations for calculating inpatient costs and outpatient costs
separately. However, this study also has several limitations. First, the purpose of the medical
costs was not completely identified. Second, measurement of biochemical parameters including
proteinuria and serum creatinine to determine subcategories was performed only once per
year. Third, this methodology cannot identify each participant because of the research design
that obtained reports composed of non-individual data; therefore, it is not possible to know the
risk of disease incidence and hospitalization with adjustment for co-morbid conditions. Finally,
this method cannot discriminate which missing claim means death or moving during 2014.
Conclusion
The results of the present study showed that the costs for CKD patients with a rapid annual
decline of eGFR were twice those of patients with stable CKD in the following year. Moreover,
starting chronic dialysis appeared to be one of the major causes of medical costs in rapid eGFR
decliners in the women of this study population. To the best of our knowledge, this is the first
study of renal disease using a large-sized cohort developed from the recently established KDB
system in Japan.
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